Trial Profile
Prostacyclin receptor agonist Selexipag in patients with pulmonary arterial hypertension and congenital heart disease
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2016
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms SELECT trial
- 20 Dec 2016 New trial record